These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25845790)

  • 1. Effects of intensive glycaemic control on ischaemic heart disease - Authors' reply.
    Gerstein HC; Miller ME
    Lancet; 2015 Mar; 385(9974):1180-1. PubMed ID: 25845790
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of intensive glycaemic control on ischaemic heart disease.
    Tsujimoto T; Yamamoto-Honda R
    Lancet; 2015 Mar; 385(9974):1180. PubMed ID: 25845791
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes: Effects of strict glycaemic control on ischaemic heart disease.
    Lim GB
    Nat Rev Cardiol; 2014 Oct; 11(10):558. PubMed ID: 25135119
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes.
    Chiasson JL; Le Lorier J
    Lancet; 2014 Nov; 384(9958):1906-7. PubMed ID: 25088436
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.
    Gerstein HC; Miller ME; Ismail-Beigi F; Largay J; McDonald C; Lochnan HA; Booth GL;
    Lancet; 2014 Nov; 384(9958):1936-41. PubMed ID: 25088437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
    Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
    Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
    White WB; Kupfer S; Zannad F
    Lancet; 2015 Oct; 386(10002):1445. PubMed ID: 26466044
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardioprotection by metformin in type 2 diabetes: what is the truth?
    Mormile R
    Minerva Endocrinol; 2019 Mar; 44(1):102. PubMed ID: 30561177
    [No Abstract]   [Full Text] [Related]  

  • 9. DIGAMI 1: 20 years later.
    Bonds DE
    Lancet Diabetes Endocrinol; 2014 Aug; 2(8):603-4. PubMed ID: 24831991
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
    Lebovitz HE
    J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes: can we stop the time bomb?
    Fisher M
    Heart; 2003 May; 89 Suppl 2(Suppl 2):ii28-30; discussion ii35-7. PubMed ID: 12695433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EXAMINE: targeting risk and treatment in diabetes.
    Riche DM; Davis C
    Lancet; 2015 Oct; 386(10002):1443-4. PubMed ID: 26466041
    [No Abstract]   [Full Text] [Related]  

  • 15. EXAMINE: targeting risk and treatment in diabetes.
    Hülsmann M; Pacher R; Neuhold S
    Lancet; 2015 Oct; 386(10002):1444-5. PubMed ID: 26466043
    [No Abstract]   [Full Text] [Related]  

  • 16. EXAMINE: targeting risk and treatment in diabetes.
    Derosa G; Maffioli P
    Lancet; 2015 Oct; 386(10002):1443. PubMed ID: 26466042
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis.
    Khodeer DM; Zaitone SA; Farag NE; Moustafa YM
    Can J Physiol Pharmacol; 2016 May; 94(5):463-76. PubMed ID: 27119311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Rydén L; Wedel H; Vestberg D; Lind M
    Eur Heart J; 2013 Feb; 34(5):374-9. PubMed ID: 23144046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [in process].
    Reisdorf S
    Med Monatsschr Pharm; 2017 Jan; 40(1):34-5. PubMed ID: 29952534
    [No Abstract]   [Full Text] [Related]  

  • 20. [New drugs for type 2 diabetes: expanding cardiovascular protection beyond type 2 diabetes?].
    Mannucci E
    G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):3S. PubMed ID: 23258122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.